Published in Mol Cancer on June 17, 2008
Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta (2011) 1.40
Regulation of microRNA processing in development, differentiation and cancer. J Cell Mol Med (2008) 1.25
Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet (2009) 1.19
Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis. Future Oncol (2010) 1.07
Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines. PLoS One (2012) 1.03
LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angew Chem Int Ed Engl (2015) 0.99
GAB2 amplifications refine molecular classification of melanoma. Clin Cancer Res (2009) 0.97
Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. Genes Chromosomes Cancer (2009) 0.96
Variability in the incidence of miRNAs and genes in fragile sites and the role of repeats and CpG islands in the distribution of genetic material. PLoS One (2010) 0.93
Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol (2014) 0.91
DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. Oncogene (2014) 0.90
Enriched environment inhibits mouse pancreatic cancer growth and down-regulates the expression of mitochondria-related genes in cancer cells. Sci Rep (2015) 0.89
Single nucleotide polymorphism array profiling of adrenocortical tumors--evidence for an adenoma carcinoma sequence? PLoS One (2013) 0.88
Genetic variation in DROSHA 3'UTR regulated by hsa-miR-27b is associated with bladder cancer risk. PLoS One (2013) 0.87
A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer. Curr Genomics (2014) 0.86
Drosha regulates hMSCs cell cycle progression through a miRNA independent mechanism. Int J Biochem Cell Biol (2011) 0.86
High-resolution genomic profiling of human papillomavirus-associated vulval neoplasia. Br J Cancer (2010) 0.85
Open access chemical probes for epigenetic targets. Future Med Chem (2015) 0.84
9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. J Med Chem (2015) 0.84
Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma. J Pathol (2013) 0.83
Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples. J Ovarian Res (2012) 0.79
Perturbation of DROSHA and DICER expression by human papillomavirus 16 oncoproteins. Virology (2017) 0.77
Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: a genome-wide follow-up study. PLoS One (2014) 0.76
LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angew Chem Weinheim Bergstr Ger (2015) 0.75
Crystallization and preliminary X-ray diffraction analysis of the middle domain of Paip1. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.75
An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer. Microarrays (Basel) (2015) 0.75
Genome-wide screening of DNA copy number alterations in cervical carcinoma patients with CGH+SNP microarrays and HPV-FISH. Int J Clin Exp Pathol (2014) 0.75
Increased expression of SKP2 is an independent predictor of locoregional recurrence in cervical cancer via promoting DNA-damage response after irradiation. Oncotarget (2016) 0.75
Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. Br J Cancer (2016) 0.75
Biological function and histone recognition of family IV bromodomain-containing proteins. J Cell Physiol (2017) 0.75
Scattered genomic amplification in dedifferentiated liposarcoma. Mol Cytogenet (2017) 0.75
The receptor for activated protein kinase C promotes cell growth, invasion and migration in cervical cancer. Int J Oncol (2017) 0.75
Epigenetic Alterations in Human Papillomavirus-Associated Cancers. Viruses (2017) 0.75
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A (2001) 68.44
The Microprocessor complex mediates the genesis of microRNAs. Nature (2004) 17.70
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev (2008) 7.87
dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics (2004) 6.78
Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol (1993) 4.67
Cervical cancer. Lancet (2003) 4.05
Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A (2001) 2.98
RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res (2006) 2.21
Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer (1997) 2.06
Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J Pathol (2006) 2.02
Oncogene amplification in solid tumors. Semin Cancer Biol (1999) 1.79
Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J Pathol (2007) 1.74
Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73
Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res (2004) 1.56
Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50
Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell (2004) 1.41
Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer (1999) 1.40
Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer (2004) 1.40
Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing. Proc Natl Acad Sci U S A (2007) 1.27
Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics (2007) 1.24
Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res (2007) 1.17
Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Res (2000) 1.11
Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome. J Pathol (2007) 1.03
Genetic alterations at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. J Natl Cancer Inst (1995) 1.00
Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine (1998) 0.97
Risk factors related to biological behaviour of precancerous lesions of the uterine cervix. Br J Cancer (1990) 0.94
HRAD1 and MRAD1 encode mammalian homologues of the fission yeast rad1(+) cell cycle checkpoint control gene. Nucleic Acids Res (1998) 0.92
Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions. Mol Cancer (2002) 0.89
Natural history and epidemiological features of genital HPV infection. IARC Sci Publ (1992) 0.89
Significance of chromosome 5 and 17 changes in the development of carcinoma of the cervix uteri. Cytogenet Cell Genet (2000) 0.82
i(5p) and del(6q) are nonrandom abnormalities in carcinoma cervix uteri. Cytogenetics of two newly developed cell lines. Cancer Genet Cytogenet (1994) 0.79
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet (2008) 5.66
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol (2008) 3.75
Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol (2009) 3.47
Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 3.39
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med (2006) 3.14
Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell (2005) 2.98
Evaluation of third-degree and fourth-degree laceration rates as quality indicators. Obstet Gynecol (2015) 2.64
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood (2009) 2.36
Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer (2008) 2.29
Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol (2012) 2.21
Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. Am J Obstet Gynecol (2011) 2.19
Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A (2004) 2.19
Clinical relevance of objectifying colposcopy. Arch Gynecol Obstet (2014) 2.03
Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell (2011) 2.01
Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol (2012) 1.98
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol (2010) 1.98
Trends and Predictors of Cerclage Use in the United States From 2005 to 2012. Obstet Gynecol (2015) 1.96
The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest (2008) 1.95
Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One (2011) 1.87
Evaluation of the VITOM in digital high-definition video exocolposcopy. J Low Genit Tract Dis (2011) 1.87
Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res (2008) 1.83
A new approach to preserve fertility by using a coated nitinol stent in a patient with recurrent cervical stenosis. Fertil Steril (2006) 1.78
Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol (2008) 1.77
Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. Am J Obstet Gynecol (2009) 1.75
Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73
Laparoscopic-assisted radical vaginal hysterectomy (LARVH): prospective evaluation of 200 patients with cervical cancer. Gynecol Oncol (2003) 1.70
Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy? Gynecol Oncol (2005) 1.68
Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat (2010) 1.63
GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol (2009) 1.63
Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol (2006) 1.62
Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor. J Pediatr Surg (2003) 1.59
Effect of surgical volume on outcomes for laparoscopic hysterectomy for benign indications. Obstet Gynecol (2012) 1.58
Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: a population-based cohort study. JAMA Surg (2013) 1.57
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol (2013) 1.57
The effect of surgeon volume on outcomes and resource use for vaginal hysterectomy. Obstet Gynecol (2010) 1.56
Trends in surgical mesh use for pelvic organ prolapse from 2000 to 2010. Obstet Gynecol (2012) 1.55
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53
Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol (2002) 1.53
Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50
FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes? Leuk Res (2009) 1.50
Comparative effectiveness research in oncology methodology: observational data. J Clin Oncol (2012) 1.49
HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol (2009) 1.48
New paradigm for prevention of cervical cancer. Eur J Obstet Gynecol Reprod Biol (2006) 1.48
CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol (2005) 1.47
Variation in ovarian conservation in women undergoing hysterectomy for benign indications. Obstet Gynecol (2013) 1.46
An in vivo and in vitro model of Plasmodium falciparum rosetting and autoagglutination mediated by varO, a group A var gene encoding a frequent serotype. Infect Immun (2008) 1.45
Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer (2006) 1.44
Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome. Int J Gynecol Cancer (2014) 1.41
Postpartum sterilization: small incision, big complication. Obstet Gynecol (2008) 1.40
Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer (2004) 1.40
Cyclodimerization of an oxoboryl complex induced by trans ligand abstraction. Angew Chem Int Ed Engl (2010) 1.39
Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology (2002) 1.37
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine (2008) 1.35
Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study. J Minim Invasive Gynecol (2005) 1.32
The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes. Cancer Res (2008) 1.30
Differentiation of phyllodes breast tumors from fibroadenomas on MRI. AJR Am J Roentgenol (2005) 1.27
Comprehensive molecular cytogenetic characterization of cervical cancer cell lines. Genes Chromosomes Cancer (2003) 1.27
Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol Oncol (2006) 1.26
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 1.22
CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology (2006) 1.20
The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol (2008) 1.17
Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol (2011) 1.16
Electron-precise coordination modes of boron-centered ligands. Chem Rev (2010) 1.14
Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int J Cancer (2005) 1.14
Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci U S A (2005) 1.14